Inve US ▾
ARARDX

Ardelyx (ARDX) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Ardelyx Q2 FY26 — Record Revenue, Revised Guidance Amid Payer Hurdles

Ardelyx reported record Q2 FY26 revenue, driven by strong demand for Izrella and Xposa, but revised its full-year Izrella guidance downward due to unexpected payer hurdles impacting patient access. The company is implementing proactive measures to address these challenges and remains committed to its path to profitability in 2027, while also advancing its pipeline and maintaining financial strength.

Highlights

5

  • Combined revenue of $118 million, up 31% year-over-year, marking the largest quarterly revenue in company history.

  • Izrella revenue grew 33% year-over-year to $86.2 million, driven by strong demand.

  • Xposa revenue increased 27% year-over-year to $31.9 million, demonstrating resilience.

  • Ended Q2 with robust liquidity of $281.8 million in cash, cash equivalents, and short-term investments.

  • Net loss narrowed to $16.7 million in Q2 2026, compared to $19.1 million in the same period last year.

Concerns

4

  • Performance fell short of expectations due to significant payer hurdles impacting new patient starts and access to Izrella.

  • Full-year 2026 guidance for Izrella was lowered to a range of $350 million to $370 million.

  • Long-term $1 billion revenue target for Izrella is being re-evaluated for timing.

  • Long-term $750 million revenue guidance for Xposa was withdrawn due to market uncertainty.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Izrella revenue
$350M-$370M
high materiality
High
Full-year 2026 Xposa revenue
$110M-$120M
medium materiality
High
Full-year 2026 OPEX
Below $500M
high materiality
High
Long-term Izrella revenue
$1B
high materiality
Medium
Long-term Xposa revenue
Withdrawn
high materiality
Low
Sustainable profitability
2027
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Izrella
Primary growth engine, experienced significant payer hurdles impacting new patient starts, but demand remains strong.
Highest demand quarter to dateStrong growth in refills and total prescriptionsHigher fulfillment rates and faster fills through IPNOne additional refill per patient annually through IPNRecord highs in Q2 demand, total riders, total prescriptions per rider, and market share since launch
$86.2M33%——
Xposa
Demonstrated resilience and solid growth across key metrics despite CMS lawsuit outcome.
Total dispenses: 33% increasePaid prescriptions: 25% increaseHighest total riders per writer since Q1 2025
$31.9M27%——

Risks & headwinds

Significant payer hurdles impacting Izrella access and new patient starts Q2 2026 and ongoing

Performance fell short of expectations; full-year 2026 Izrella guidance lowered to $350M-$370M.

Mitigation:Doubled field reimbursement team, reinforced Izrella Pharmacy Network (IPN), expanded sales force to 144 representatives, initiating new direct-to-consumer activities, engaging payer community.

CMS lawsuit outcome affirming oral-only phosphate lowering drugs in the bundle for Xposa June 26 (DC Circuit Court of Appeals decision)

No longer pursuing further litigation on this matter.

Mitigation:Committed to ensuring patient access to Xposa, enhancing commercial approach, refining salesforce deployment, strengthening engagement with HCPs and dialysis organizations.

Uncertainty in Xposa market dynamics (post-Tdapha period, new QIP, new binders) Ensuing months

Withdrawal of $750 million long-term revenue guidance for Xposa.

Mitigation:Revisiting internal assumptions and will provide a better-informed view after assessing market transitions.

What to watch in Q3 FY26

Izrella patient access and new patient starts

Back half of this year
Current Slowed by increased payer step edits and stringent prior authorizations
Target Acceleration of demand and improved pull-through

Why it matters

Directly impacts Izrella revenue growth and achievement of revised guidance.

So we feel confident around those four actions that we've put in place that we'll be able to accelerate demand as well as improve pull through as we go through the back half of this year.

Find out whether ARDX delivers this. Inve re-checks your case every morning.

Q&A highlights

Can you discuss the underlying demand metrics for Izrella in Q2 and July, and how they support the revised full-year guidance, including the pushes and pulls factored in?

Management confirmed strong refills and total prescriptions for Izrella, noting Q2 was the highest demand quarter to date. They highlighted the Izrella Pharmacy Network (IPN) for higher fulfillment and refills. All identified friction and current performance have been factored into the revised guidance.

“So we feel confident around those four actions that we've put in place that we'll be able to accelerate demand as well as improve pull through as we go through the back half of this year, that we'll continue to be able to have that control growth that we expect.”

asked by Ryan (for Ruana Ruiz, Lear Inc. Partners) · answered by Eric Foster

2 min read 5 chapters

Detailed narrative

Izrella Access Challenges and Mitigation Strategies

Ardelyx reported that Izrella's performance fell short of expectations due to significant payer hurdles, including more step edits and stringent prior authorizations, which have slowed new patient starts. To address these challenges, the company has doubled its field reimbursement team, reinforced the Izrella Pharmacy Network (IPN) to improve fulfillment rates and adherence, expanded its sales organization to 144 representatives for increased HCP engagement, and is initiating new direct-to-consumer activities in the second half of the year to boost patient awareness and drive demand.

Xposa Market Dynamics and Guidance Withdrawal

Despite strong Q2 performance, the company withdrew its long-term $750 million revenue guidance for Xposa. This decision follows the DC Circuit Court of Appeals affirming the dismissal of their lawsuit against CMS, meaning oral-only phosphate lowering drugs remain in the bundle. Management cited uncertainty around the post-Tdapha period, the implications of a new phosphorus quality measure (QIP), and the development of new binders as reasons to re-evaluate internal assumptions and provide a better-informed view in the future.

Pipeline Advancement and Intellectual Property

Ardelyx is investing in its future by advancing Tanapanoor, a next-generation NHG3 inhibitor. The company is building a robust patent estate for Tanapanoor, anchored by multiple Orange Book listed patents, including the 299 patent, which provides protection through 2042. Additionally, the Excel Phase III clinical trial for CIC is on track, with enrollment progressing well, and data readout expected around a year from the call date, leveraging existing sales force synergies.

Financial Strength and Capital Allocation Priorities

The company emphasized its strengthening balance sheet, disciplined expense management, and commitment to achieving sustainable profitability in 2027. Ardelyx ended Q2 with $281.8 million in cash and short-term investments and drew down $50 million from an existing arrangement to enhance flexibility. Capital allocation priorities remain consistent: accelerating Izrella growth, actively progressing the pipeline, and maintaining financial strength.

Business Development and Long-term Vision

Ardelyx is actively pursuing business development opportunities to expand its pipeline, noting a substantial number of opportunities are being evaluated. Management expressed optimism about building the pipeline, leveraging the cash generated by commercial products. The company maintains its enthusiasm and belief in its competitive position and strategy, aiming to create long-term value for patients and shareholders.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.